BACKGROUND Studies performed over the past decade have identified fairly consistent epidemiological patterns of risk factors for visceral leishmaniasis (VL) in the Indian subcontinent. METHODS AND PRINCIPAL FINDINGS To inform the current regional VL elimination effort and identify key gaps in knowledge, we performed a systematic review of the literature, with a special emphasis on data regard...

BACKGROUND Co-infection of leishmaniasis and HIV is increasingly reported. The clinical presentation of leishmaniasis is determined by the host immune response to the parasite; as a consequence, this presentation will be influenced by HIV-induced immunosuppression. As leishmaniasis commonly affects the skin, increasing immunosuppression changes the clinical presentation, such as in post-kala-az...

Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection,...

Submit Manuscript | http://medcraveonline.com rash which is on the rise. Clinical symptoms of VL disease in the initial infective stages overlap with symptoms of other diseases that make it difficult to diagnose. The VL disease is still a major health challenge in parts of the developing world having people in the most impoverished conditions where the disease is endemic. VL is caused by parasi...

BACKGROUND Immunochromatographic based rk39 antibody detection test became popular for the diagnosis of visceral leishmaiasis (VL) because of high sensitivity, rapidity, easy to interpret, and cost effectiveness. However, false positive result after complete cure of the patients is the major limitation with this test. The aim of the study to access the usefulness of non-invasive samples i.e. ur...

Visceral leishmaniasis (VL) or kala-azar, a vector-borne protozoan disease, shows endemicity in larger areas of the tropical, subtropical and the Mediterranean countries. WHO report suggested that an annual incidence of VL is nearly 200,000 to 400,000 cases, resulting in 20,000 to 30,000 deaths per year. Treatment with available anti-leishmanial drugs are not cost effective, with varied efficac...

BACKGROUND Visceral leishmaniasis (VL), commonly known as kala-azar is a systemic disease caused by parasitic protozoan species of genus Leishmania and transmitted by species of Phlebotomus (sand flies). It is a poverty-related disease and associated with malnutrition, displacement, poor housing, weakness of the immune system and lack of resources. For the success of prevention and control prog...

background: visceral leishmaniasis (vl) or kala-azar is a parasitic disease caused by the species of leishmania donovani complex. mediterranean type of the disease is endemic in some parts of iran and more than 95% of cases were reported in children up to 12 years of age. this study was performed to determine the seroprevalence of vl in the rural areas of dashti district from bushehr province. ...

background visceral leishmaniasis(vl) is a spreading potentially fatal zoonosis in iran mimicking many other diseases in infancy which differs from vl in some other regions in terms of it’s clinical characteristics and response to therapy; earlier and better management is quite effective for life saving. patients and methods all cases with final diagnosis of vl,2months to 12 years who were disc...